Combine dengue vaccines to optimize effectiveness

Alejandro Macias; Guillermo Ruiz-Palacios; Jose Ramos-Castaneda

doi:10.1016/j.vaccine.2020.05.088

Combine dengue vaccines to optimize effectiveness

Vaccine. 2020 Jun 26;38(31):4801-4804. doi: 10.1016/j.vaccine.2020.05.088. Epub 2020 Jun 5.

Authors

Alejandro Macias¹, Guillermo Ruiz-Palacios², Jose Ramos-Castaneda³

Affiliations

¹ Universidad de Guanajuato, Guanajuato, Mexico. Electronic address: [email protected].
² Instituto Nacional de Ciencias Medicas y Nutrición Salvador Zubirán, Ciudad de México, Mexico. Electronic address: [email protected].
³ Instituto Nacional de Ciencias Medicas y Nutrición Salvador Zubirán, Ciudad de México, Mexico; Instituto Nacional de Salud Publica, Cuernavaca, Morelos, Mexico. Electronic address: [email protected].

PMID: 32507334
DOI: 10.1016/j.vaccine.2020.05.088

Abstract

Developing a completely effective and safe dengue vaccine has been a complicated process. Dengvaxia®, by Sanofi-Pasteur, and recently TAK003, by Takeda, have strengths and weaknesses, but they seem to complement each other. In this work, we elaborate a rationale that could be applicable in a combined program of these vaccines for the control of dengue.

Keywords: Dengue; Public health; Vaccination program; Vaccine.

MeSH terms

Dengue Vaccines*
Dengue* / prevention & control
Humans
Vaccination
Vaccines, Attenuated

Substances

Dengue Vaccines
Vaccines, Attenuated